David Grinblatt to Combined Modality Therapy
This is a "connection" page, showing publications David Grinblatt has written about Combined Modality Therapy.
Connection Strength
0.047
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.017
-
Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
Score: 0.009
-
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apher. 1999; 14(1):31-4.
Score: 0.008
-
High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant. 1998 Jan; 21(2):127-32.
Score: 0.007
-
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant. 1995 Jun; 15(6):935-42.
Score: 0.006